Next Article in Journal
Preparation of Ruthenium Olefin Metathesis Catalysts Immobilized on MOF, SBA-15, and 13X for Probing Heterogeneous Boomerang Effect
Next Article in Special Issue
The Role of Support Hydrophobicity in the Selective Hydrogenation of Enones and Unsaturated Sulfones over Cu/SiO2 Catalysts
Previous Article in Journal
Self-Metathesis of Methyl Oleate Using Ru-NHC Complexes: A Kinetic Study
Previous Article in Special Issue
Supported Tris-Triazole Ligands for Batch and Continuous-Flow Copper-Catalyzed Huisgen 1,3-Dipolar Cycloaddition Reactions
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Catalysts
Volume 10
Issue 4
10.3390/catal10040436
catalysts-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Activated Carbon Supported Hafnium(IV) Chloride as an Efficient, Recyclable, and Facile Removable Catalyst for Expeditious Parallel Synthesis of Benzimidazoles

by
Xiao-Chong Peng
1,
Shan-Shan Gong
1,
De-Yun Zeng
1,
Shu-Wang Duo
2,* and
Qi Sun
1,*
1
Jiangxi Key Laboratory of Organic Chemistry, Jiangxi Science and Technology Normal University, 605 Fenglin Avenue, Nanchang 330013, Jiangxi, China
2
Jiangxi Key Laboratory of Surface Engineering, Jiangxi Science and Technology Normal University, 605 Fenglin Avenue, Nanchang 330013, Jiangxi, China
*
Authors to whom correspondence should be addressed.
Catalysts 2020, 10(4), 436; https://doi.org/10.3390/catal10040436
Submission received: 19 March 2020 / Revised: 10 April 2020 / Accepted: 14 April 2020 / Published: 17 April 2020
(This article belongs to the Special Issue Supported Metal Catalysts and Their Applications in Fine Chemicals)
Browse Figures
Versions Notes

Abstract

A highly efficient method for parallel synthesis of a diversity of 1,2-disubstituted benzimidazoles from N-substituted phenylenediamines and aldehydes has been developed by using 10 mol% HfCl4 on activated carbon (HfCl4/C) as the catalyst. The newly reported HfCl4/C catalyst not only mediated fast and clean formation of benzimidazoles but also could be easily removed from the reaction solution and reused up to eight times. Scanning electron microscope (SEM) and thermal desorption studies showed that activated carbon could reversibly adsorb and release Hf(IV) in ethanol upon cooling and heating, thereby serving as a thermal-controlled solid support.

Graphical Abstract

1. Introduction

As one of the most important heterocyclic scaffolds, 1,2-disubstituted benzimidazole has been extensively employed in the development of novel pharmaceutical agents and functional materials [1,2,3]. In contemporary drug discovery, a huge number of benzimidazole derivatives have been synthesized and utilized as anti-infective, anti-inflammatory, antihypertensive, antitumor, antiallergic, antidiabetic, analgesic, and proton pump inhibitory agents [4,5,6,7].
In our previous research, we found that the synthesis of 2-aminovinyl benzimidazoles represented a huge challenge to the commonly known synthetic methods for benzimidazoles. To promote the condensation of 1,2-phenylenediamines with N-arylated 3-aminoacroleins, both acidic catalysts (e.g., PPA [8] and BF3∙Et2O [9]) and oxidative reagents (e.g., DDQ [10], MnO2 [11], I2 [12], and Oxone [13]) were tested. However, none of these methods afforded the desired 2-aminovinyl benzimidazoles, because the conjugation of electron-donating aniline significantly lowered electropositivity of the carbonyl in 3-aminoacroleins. Surprisingly, we found that the non-toxic and inexpensive Group IVB transition metal salts, such as ZrOCl2∙8H2O, ZrCl4 [14], and Cp2ZrCl2 [15], exhibited dramatic catalytic effects on the formation of 2-aminovinyl benzimidazoles due to their strong activation capability on carbonyl group. Yin and Gao also reported that the metallocenes of Ti(IV) [16] and Zr(IV) [17] were highly efficient Lewis acids for other carbonyl-transformation reactions. In recent years, HfCl4, another closely related Group IVB transition metal salt, was revealed to possess even superior activities in many metal Lewis acid-catalyzed reactions [18,19,20], especially those involving carbonyl activation [21,22,23,24]. In addition, it is noteworthy that ZrOCl2∙8H2O, ZrCl4, and HfCl4 showed high catalytic activity in the synthesis of 2-substituted benzimidazoles from o-phenylenediamines and orthoesters [25]. As equivalents of carboxylic acids, orthoesters are distinct from aldehyde. The condensation of o-phenylenediamines with orthoesters does not require an extra oxidation step to form benzimidazoles as that of o-phenylenediamines with aldehydes. Though aldehydes are more favorable starting materials compared to orthoesters due to their much higher commercial availability, the application of HfCl4 as a catalyst for the reaction of o-phenylenediamines and aldehydes has never been explored before.
Inspired by these precedent reports, we extended our research to utilize HfCl4 as a strong carbonyl-activating catalyst to promote the condensation of N-substituted o-phenylenediamines and aldehydes for expeditious synthesis of 1,2-disubstituted benzimidazoles. In this paper, we report the first utilization of HfCl4 on activated carbon (HfCl4/C) as a novel, efficient, recyclable, and easily removable catalyst for parallel synthesis of a diversity of 1,2-disubstituted benzimidazoles. The scanning electron microscope (SEM) and thermal desorption data elucidated that HfCl4 adsorbed on activated carbon could be partially released in refluxing ethanol and efficiently redeposited on activated carbon upon cooling to ambient temperature.

2. Results and Discussion

In the preliminary experiments, N-phenyl-o-phenylenediamine (1{1}) and benzaldehyde (2{1}) in a 1:1 ratio were reacted in the presence or absence of 10 mol% Group IVB metal catalysts in ethanol at room temperature without inert gas protection. The data listed in Table 1 showed that the control reaction without catalyst was sluggish (96 h) and afforded product 3{1,1} in 81% yield. TiCl4 shortened the reaction time to 20 h, but the yield of 3{1,1} was low due to the formation of polar byproducts. All Zr(IV)-catalyzed reactions went to completion in 16–20 h with 89%–92% yields of 3{1,1}. This result was in accordance with a previous report on ZrOCl2∙8H2O-catalyzed benzimidazole synthesis under solvent-free conditions [26]. Interestingly, HfCl4-catalyzed reaction was remarkably faster (12 h) and higher-yielding (96%). It is noteworthy that when the amount of HfCl4 was reduced to 5 mol%, the reaction time was prolonged to 16 h, but the product yield was not affected. Further experiments showed that the catalytic effect was drastically diminished when the amount of HfCl4 was decreased below 3 mol%.
As expected, increasing temperature significantly accelerated the reaction rate (Table 2, entries 1–4). When the reaction with 5 mol% HfCl4 was performed in refluxing ethanol, the reaction time was shortened to only 1 h without affecting the yield of 3{1,1}. The solvent effect was also investigated (Table 2, entries 5–8). The HfCl4-catalyzed reactions proceeded with comparable yields in DMF, CH3CN, and dichloroethane (DCE) except that the reaction in DCE was much slower. The reaction in THF generated a significant amount of polar byproducts and required 6 h to complete. It was interesting to observe that the reaction solution immediately turned into orange color upon addition of HfCl4 (Table 2, entry 4). Meanwhile, TLC showed that most of 1{1} and 2{1} starting materials disappeared quickly and were converted into the corresponding colored imine and benzimidazoline intermediates in the presence of HfCl4. In contrast, the formation of the colored intermediates was much slower without a catalyst. These results indicated that HfCl4 promoted the formation of both imine and benzimidazoline intermediates, which is similar to the catalytic mechanism of Hf(IV) on the formation of fluorinated benzimidazolines elucidated by NMR tracing data [27]. Subsequently, aerial oxidation of the benzimidazoline intermediate smoothly afforded the desired benzimidazole 3{1,1} as described in many precedent reports [28,29,30].
To test the possibility to recycle the catalyst, we loaded the HfCl4 onto a series of activated solid supports (5% w/w). Under the optimized reaction conditions, 10 mol% of the supported HfCl4 was applied as the catalyst. The results listed in Table 3 showed that the catalytic effects of HfCl4/C, HfCl4/Al2O3, and HfCl4/K-10 montmorillonite were similar, where the HfCl4/SiO2-catalyzed reaction required a longer reaction time (2 h). However, these supported catalysts exhibited huge differences upon reuse. Compared with the other three supported catalysts whose potencies remarkably decreased in the 2nd round, HfCl4/C showed consistent catalytic activity in terms of both yield and reaction rate for 4 rounds. As shown in Figure 1, the yields of 3{1,1} with recycled HfCl4/C catalyst could be maintained (over 95%) up to 8 rounds. However, the reaction time was gradually prolonged from 1 to 2 h in the 5th to 8th rounds.
To determine how much HfCl4 was released into ethanol as homogeneous catalyst at 80 °C, HfCl4/C (5% w/w, 500 mg) was added to ethanol (16 mL) and refluxed for 30 min. The solid was filtered while the solution was still at 80 °C. The weight loss data (Table 4) showed that, in the first use, 30% of HfCl4 desorbed from the surface of activated carbon and was released into the reaction solution. It took 5 times before the HfCl4 was completely washed off. If ethanol was cooled to room temperature before filtration, mimicking the reaction workup procedure, the weight loss was almost negligible after 5 rounds. These results indicated that activated carbon could function as an efficient thermal-controlled sponge that enabled reversible adsorption and release of HfCl4 catalyst in ethanol upon cooling and heating.
As depicted in the scanning electron microscope (SEM) images of HfCl4/C samples, most HfCl4 initially loaded onto activated carbon appeared as small crystalline-like solids (Figure 2A). After 5 rounds of hot filtration, the surface of the solid support was as clean as that of pure activated carbon. In contrast, the HfCl4/C sample, which was filtered after cooling for 5 times still adsorbed Hf(IV) salt as disordered and amorphous solids (Figure 2B). These results were in good accordance with the thermal desorption experiments mentioned above. Meanwhile, the energy dispersive spectrum (EDS) analysis of the samples confirmed that the solids on the surface of activated carbon were hafnium salts (Figure 2). It is worth noting that the Cl element almost disappeared after 5 rounds of refluxing/cooling/filtration, indicating that chloride was gradually exchanged to ethoxide upon repeated use. However, the recyclability of the catalyst suggested that the counter ion had relatively less important effect on the catalytic activity.
Since HfCl4 was tightly adsorbed on activated carbon at room temperature, we were interested to clarify whether HfCl4/C could catalyze the formation of benzimidazole 3{1,1} in a heterogeneous manner. The experimental result showed that HfCl4/C (10 mol%) indeed promoted the formation of 3{1,1} at room temperature. However, as expected, the heterogeneous catalysis (89%, 24 h) was less efficient than the homogeneous catalysis (Table 1, entry 6). These results suggested that, under the refluxing conditions, HfCl4/C catalyzed the formation of benzimidazole 3{1,1} in a combined homogenous/heterogeneous manner.
Other than the high potency and recyclability of HfCl4/C, another huge advantage of this novel catalyst was that it could be easily removed from the reaction solution without leaving residual metal Lewis acid in the crude product. Therefore, HfCl4/C may be applied as an ideal catalyst for expeditious parallel synthesis of benzimidazole derivatives. To prove this point, a diversity of N-substituted o-phenylenediamines (1{1–9}) and aldehydes (2{1–10}) were employed as substrates and total 28 benzimidazoles (3{1–9,1–10}) were prepared on a parallel synthesizer with HfCl4/C as the catalyst in one single batch. The reactions were heated in tightly capped vials at 80 °C for 1 h. After the reactions were cooled to ambient temperature, HfCl4/C was removed by centrifuge, and the supernatants were concentrated to afford the crude products in 97%–101% yields. The purity of crude benzimidazoles (3) was determined to be 91.9%–99.0% by analytical HPLC. Further flash chromatography afforded 28 benzimidazoles (3) in excellent isolated yields ranging from 87% to 96% (Figure 3).

3. Materials and Methods

3.1. General Methods

Chemical reagents (Aladdin, Shanghai, China) were obtained from a commercial supplier. Supported catalysts were prepared according to the methods described below. All reactions were performed in commercial analytical reagent (AR) grade solvents (Zhiyuan Chemicals, Tianjin, China) and monitored by thin layer chromatography on plates coated with 0.25 mm silica gel 60 F254 (Qingdao Haiyang Chemicals, Qingdao, China). TLC plates were visualized by UV irradiation (254 nm). The parallel synthesis was performed in 28 tightly capped reaction vials (10 mL) on an aluminum reaction heating block with 48 wells. Melting points were determined with a Thomas-Hoover melting point apparatus and uncorrected (Thomas Scientific, Swedesboro, NJ, USA). NMR spectra were obtained with a Bruker AV-400 instrument (Bruker BioSpin, Faellanden, Switzerland) with chemical shifts reported in parts per million (ppm, δ) and referenced to CDCl3. The NMR spectra of new compounds were provided in Supplementary Materials (Figures S1–S38). IR spectra were recorded on a Bruker Vertex-70 spectrometer (Bruker Optics, Billerica, MA, USA). High-resolution mass spectra were reported as m/z and obtained with a Dalton micrOTOF-Q II spectrometer (Bruker Daltonics, Billerica, MA, USA). HPLC traces were recorded on an analytical Agilent 1260 Infinity II LC instrument (Angilent Technologies, Palo Alto, CA, USA) equipped with a C18 analytical Angilent Zorbax column (4.6 × 150 mm, 5 μm; flow rate = 1.0 mL/min; 70% MeOH in ddH2O over 15 min; UV detection at 270 nm). The morphology and chemical composition of HfCl4/C samples were investigated by a Zeiss Sigma field emission scanning electron microscope (Zeiss microscopy, Jena, Germany).

3.2. General Procedure for Preparation of HfCl4/C Catalyst

Before impregnation of HfCl4, commercial activated carbon (200 mesh) was pretreated with 30% HNO3 at 90 °C for 4 h, washed ddH2O until pH reached 7, and dried at 120 °C for 12 h. HfCl4 (0.5 g, 5% w/w) was dissolved in absolute ethanol (50 mL). Then, pretreated activated carbon (9.5 g) was added and sonicated for another 30 min at ambient temperature. Ethanol was then removed under reduced pressure to afford HfCl4/C.

3.3. General Procedure for Preparation of Other Supported HfCl4 Catalysts

Before impregnation of HfCl4, commercial silica gel (300–400 mesh), aluminum oxide (200–300 mesh), and K-10 montmorillonite were heated in an oven at 150 °C for 24 h. HfCl4 (0.5 g, 5% w/w) was dissolved in absolute ethanol (50 mL). Then, pretreated solid supports (9.5 g) was added and stirred for 30 min and sonicated for another 30 min at ambient temperature. Ethanol was then removed under reduced pressure to afford HfCl4/SiO2, HfCl4/Al2O3, and HfCl4/K-10 montmorillonite.

3.4. General Synthetic Procedure and Characterization of Benzimidazoles

To a solution of N-substituted o-phenylenediamines (0.15 mmol) and aldehyde (0.15 mmol) in ethanol (3 mL) was added HfCl4/C (0.015 mmol, 5% w/w). The reaction was stirred at 80 °C for 1 h. After the reaction was cooled to ambient temperature, HfCl4/C was removed by centrifuge and supernatant was concentrated under reduced pressure. Flash column chromatography on silica gel (petroleum ether:ethyl acetate = 4:1) afforded benzimidazole in pure form.
1,2-Diphenyl-5-methoxycarbonyl-1H-benzo[d]imidazole (3{2,1}): a white solid; mp 147–148 °C. 1H NMR (400 MHz, CDCl3): δ 8.60 (s, 1H), 7.98 (d, J = 8.1 Hz, 1H), 7.61–7.47 (m, 5H), 7.38–7.20 (m, 6H), 3.95 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 167.5, 154.1, 142.6, 140.3, 136.5, 130.1, 129.9, 129.5, 129.0, 128.4, 127.3, 125.2, 124.9, 122.2, 110.2, 52.2 ppm; IR: vmax 3058, 2924, 2853, 1721, 1619, 1596, 1496, 1478, 1448, 1024, 982, 924, 892, 827, 804, 778 cm−1; HRMS (ESI+): m/z calcd for C21H17N2O2 [M+H]+ 329.1285; found 329.1280.
2-(4-Fluorophenyl)-1-phenyl-5-methoxycarbonyl-1H-benzo[d]imidazole (3{2,4}): a white solid; mp 156–157 °C. 1H NMR (400 MHz, CDCl3): δ 8.57 (s, 1H), 7.97 (d, J = 8.5 Hz, 1H), 7.59–7.47 (m, 5H), 7.29 (d, J = 7.2 Hz, 2H), 7.22 (d, J = 8.2 Hz, 1H), 7.04–6.95 (m, 2H), 3.95 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 167.6, 165.0, 162.5, 153.3, 142.8, 140.5, 136.6, 131.7, 131.6, 130.3, 129.3, 127.9, 125.9, 125.5, 125.2, 122.4, 115.9, 115.7, 110.3, 52.3 ppm; IR: vmax 3062, 2921, 2852, 1709, 1618, 1596, 1523, 1497, 1473, 1437, 1045, 987, 897, 839, 802, 765 cm−1; HRMS (ESI+): m/z calcd for C21H16FN2O2 [M+H]+ 347.1190; found 347.1187.
2-(Furan-2-yl)-1-phenyl-5-methoxycarbonyl-1H-benzo[d]imidazole (3{2,6}): a light yellow solid; mp 130–131 °C. 1H NMR (400 MHz, CDCl3): δ 8.53 (s, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.65–7.56 (m, 3H), 7.52–7.45 (m, 1H), 7.43–7.36 (m, 2H), 7.07 (d, J = 8.6 Hz, 1H), 6.39–6.31 (m, 1H), 6.16–6.11 (m, 1H), 3.92 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 167.5, 145.9, 144.7, 144.1, 142.7, 140.3, 136.0, 130.2, 129.9, 127.9, 125.4, 125.2, 122.2, 113.1, 111.7, 109.9, 52.2 ppm; IR: vmax 3054, 2948, 2825, 1596, 1514, 1481, 1467, 1458, 1043, 995, 976, 928, 785 cm-1; HRMS (ESI+): m/z calcd for C19H15N2O3 [M+H]+ 319.1077; found 319.1082.
(E)-1-Phenyl-2-styryl-5-methoxycarbonyl-1H-benzo[d]imidazole (3{2,9}): a white solid; mp 195–196 °C. 1H NMR (400 MHz, CDCl3): δ 8.54 (s, 1H), 8.02–7.91 (m, 2H), 7.69–7.55 (m, 3H), 7.51–7.41 (m, 4H), 7.40–7.28 (m, 3H), 7.19 (d, J = 8.8 Hz, 1H), 6.83 (d, J = 15.6 Hz, 1H), 3.96 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 167.7, 152.8, 143.1, 139.9, 138.4, 136.0, 135.4, 130.3, 129.5, 129.4, 129.0, 127.7, 127.6, 125.6, 124.9, 121.9, 113.7, 109.9, 52.2 ppm; IR: vmax 3058, 2955, 2839, 1708, 1611, 1498, 1434, 1015, 797 cm−1; HRMS (ESI+): m/z calcd for C23H19N2O2 [M+H]+ 355.1441; found 355.1440.
1,2-Diphenyl-5-(trifluoromethyl)-1H-benzo[d]imidazole (3{3,1}): a white solid; mp 145–146 °C. 1H NMR (400 MHz, CDCl3): δ 8.06 (s, 1H), 7.53–7.36 (m, 6H), 7.32–7.14 (m, 6H) ppm; 13C NMR (100 MHz, CDCl3): δ 154.5, 142.6, 139.3, 136.6, 130.2, 130.1, 129.6, 129.4, 129.2, 128.5, 127.4, 125.6, 123.6, 120.3, 117.7, 111.0 ppm; IR: vmax 3056, 2926, 2845, 1621, 1597, 1500, 1476, 1450, 1435, 1047, 1027, 978, 937, 891, 860, 823, 771 cm−1; HRMS (ESI+): m/z calcd for C20H14F3N2 [M+H]+ 339.1104; found 339.1109.
2-Cyclohexyl-1-phenyl-5-(trifluoromethyl)-1H-benzo[d]imidazole (3{3,7}): a white solid; mp 93–94 °C. 1H NMR (400 MHz, CDCl3): δ 8.06 (s, 1H), 7.65–7.54 (m, 3H), 7.41 (d, J = 8.4 Hz, 1H), 7.34 (d, J = 6.8 Hz, 2H), 7.11 (d, J = 8.4 Hz, 1H), 2.77–2.65 (m, 1H), 1.96–1.62 (m, 6H), 1.38–1.11 (m, 4H) ppm; 13C NMR (100 MHz, CDCl3): δ 161.5, 142.3, 138.6, 135.6, 130.3, 129.5, 127.6, 125.2, 119.5, 117.1, 110.5, 36.4, 32.0, 29.8, 26.2, 25.8 ppm; IR: vmax 3045, 2930, 2855, 1727, 1623, 1598, 1506, 1442, 1042, 926, 883, 809, 767 cm−1; HRMS (ESI+): m/z calcd for C20H20F3N2 [M+H]+ 345.1573; found 345.1566.
2-Pentyl-1-phenyl-5-(trifluoromethyl)-1H-benzo[d]imidazole (3{3,8}): colorless oil; 1H NMR (400 MHz, CDCl3): δ 8.05 (s, 1H), 7.69–7.52 (m, 3H), 7.43 (d, J = 8.5, 1H), 7.35 (d, J = 8.1 Hz, 2H), 7.16 (d, J = 8.5 Hz, 1H), 2.78 (t, J = 7.6 Hz, 2H), 1.87–1.72 (m, 2H), 1.34–1.21 (m, 4H), 0.83 (t, J = 6.9 Hz, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 157.7, 142.3, 138.6, 135.6, 130.2, 129.5, 127.4, 119.6, 116.9. 110.4, 31.6, 27.8, 27.5, 22.4, 14.0 ppm; IR: vmax 3064, 2847, 2828, 1586, 1529, 1481, 1475, 1444, 1023, 998, 974, 929, 784 cm−1; HRMS (ESI+): m/z calcd for C19H20F3N2 [M+H]+ 333.1573; found 333.1574.
1-Benzyl-2-(pyridin-2-yl)-5-(trifluoromethyl)-1H-benzo[d]imidazole (3{4,5}): a white solid; mp 160–161 °C. 1H NMR (400 MHz, CDCl3): δ 8.75 (d, J = 7.2 Hz, 1H), 8.56 (d, J = 7.6 Hz, 1H), 8.26 (s, 1H), 7.96 (dd, J1 = J2 = 7.8 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.51 (d, J = 8.5 Hz, 1H), 7.49–7.43 (m, 1H), 7.41–7.32 (m, 3H), 7.27 (d, J = 7.6 Hz, 2H), 6.32 (s, 2H) ppm; 13C NMR (100 MHz, CDCl3): δ 151.8, 150.0, 148.8, 142.2, 138.7, 137.0, 136.9, 128.7, 127.6, 126.8, 125.8, 124.9, 124.3, 123.5, 120.3, 117.8, 111.2, 49.2 ppm; IR: vmax 3066, 2938, 2854, 1621, 1584, 1492, 1447, 1429, 1045, 994, 974, 930, 895, 840, 792 cm−1; HRMS (ESI+): m/z calcd for C20H15F3N3 [M+H]+ 354.1213; found 354.1216.
(E)-1-Cyclohexyl-2-styryl-1H-benzo[d]imidazole (3{5,9}): colorless oil; 1H NMR (400 MHz, CDCl3): δ 8.01 (d, J = 15.7 Hz, 1H), 7.82 (d, J = 7.8 Hz, 1H), 7.67 (d, J = 7.6 Hz, 2H), 7.59 (d, J = 8.1 Hz, 1H), 7.51–7.33 (m, 3H), 7.32–7.16 (m, 3H), 4.51–4.39 (m, 1H), 2.42–2.23 (m, 2H), 2.04 (m, 4H), 1.88 (m, 1H), 1.65–1.22 (m, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 150.0, 143.2, 136.9, 135.7, 133.8, 128.4, 128.3, 126.7, 121.6, 121.5, 119.1, 113.6, 55.6, 31.2, 25.7, 24.9 ppm; IR: vmax 3064, 2937, 2828, 1589, 1532, 1488, 1474, 1456, 1023, 986, 973, 929, 782 cm−1; HRMS (ESI+): m/z calcd for C21H23N2 [M+H]+ 303.1856; found 303.1843.
2-(2-(4-Methoxyphenyl)-1-phenyl-1H-benzo[d]imidazol-5-yl)benzo[d]thiazole (3{6,3}): a light yellow solid; mp 209–210 °C. 1H NMR (400 MHz, CDCl3): δ 8.43 (s, 1H), 8.06–7.97 (m, 2H), 7.82 (d, J = 7.8 Hz, 1H), 7.50–7.37 (m, 6H), 7.32–7.17 (m, 4H), 6.76 (d, J = 8.2 Hz, 2H), 3.72 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 168.9, 160.9, 154.4, 153.9, 143.3, 139.3, 136.8, 135.1, 131.0, 130.1, 129.0, 128.9, 127.5, 126.2, 124.9, 123.0, 122.7, 121.9, 121.6, 119.5, 113.9, 110.8, 55.3 ppm; IR: vmax 3062, 2931, 2839, 1719, 1606, 1530, 1501, 1479, 1432, 1020, 908, 835, 792 cm−1; HRMS (ESI+): m/z calcd for C27H20N3OS [M+H]+ 434.1322; found 434.1318.
2-(1-Phenyl-2-(pyridin-2-yl)-1H-benzo[d]imidazol-5-yl)benzo[d]thiazole (3{6,5}): a white solid; mp 128–129 °C. 1H NMR (400 MHz, D2O): δ 8.68 (s, 1H), 8.52 (d, J = 4.6 Hz, 1H), 8.28 (d, J = 8.6 Hz, 1H), 8.25–8.17 (m, 2H), 8.03 (d, J = 7.9 Hz, 1H), 7.88 (dd, J1 = J2 = 7.8 Hz, 1H), 7.66–7.56 (m, 4H), 7.53–7.42 (m, 4H), 7.40–7.34 (m, 1H) ppm; 13C NMR (100 MHz, D2O): δ 168.7, 154.3, 152.1, 149.1, 149.0, 142.9, 139.6, 137.3, 136.5, 135.1, 129.4, 129.2, 128.4, 127.3, 126.2, 124.9, 124.7, 123.9, 123.4, 123.0, 121.5, 120.1, 111.4 ppm; IR: vmax 3058, 2931, 2856, 1726, 1588, 1496, 1442, 1018, 971, 871, 790 cm−1; HRMS (ESI+): m/z calcd for C25H17N4S [M+H]+ 405.1168; found 405.1154.
2-(2-(Furan-2-yl)-1-phenyl-1H-benzo[d]imidazol-5-yl)benzo[d]thiazole (3{6,6}): a light yellow solid; mp 143–144 °C. 1H NMR (400 MHz, CDCl3): δ 8.51 (s, 1H), 8.14–8.03 (m, 2H), 7.89 (d, J = 7.9 Hz, 1H), 7.68–7.57 (m, 3H), 7.55–7.32 (m, 5H), 7.16 (d, J = 8.5 Hz, 1H), 6.41–6.34 (m, 1H), 6.16 (d, J = 3.4 Hz, 1H) ppm; 13C NMR (100 MHz, CDCl3): δ 168.1, 153.7, 145.1, 144.0, 143.6, 142.8, 138.6, 134.6, 129.9, 129.6, 128.6, 127.3, 125.7, 124.4, 122.6, 122.4, 121.0, 119.1, 112.4, 111.1, 110.1 ppm; IR: vmax 3052, 2945, 2828, 1620, 1593, 1499, 1470, 1429, 1026, 973, 911, 861, 822, 762 cm−1; HRMS (ESI+): m/z calcd for C24H16N3OS [M+H]+ 394.1009; found 394.1003.
2-(2-Pentyl-1-phenyl-1H-benzo[d]imidazol-5-yl)benzo[d]thiazole (3{6,8}): a light yellow solid; mp 128–129 °C. 1H NMR (400 MHz, CDCl3): δ 8.43 (s, 1H), 8.12–8.00 (m, 2H), 7.87 (d, J = 7.8 Hz, 1H), 7.63–7.50 (m, 3H), 7.45 (dd, J1 = J2 = 7.6 Hz, 1H), 7.41–7.29 (m, 3H), 7.16 (d, J = 8.4 Hz, 1H), 2.78 (t, J = 7.7 Hz, 2H), 1.88–1.72 (m, 2H), 1.37–1.21 (m, 4H), 0.84 (t, J = 6.8 Hz, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 168.5, 156.6, 153.9, 142.5, 138.1, 135.2, 134.6, 129.5, 128.7, 127.9, 126.8, 125.6, 124.3, 122.4, 121.7, 121.0, 118.6, 109.6, 31.0, 27.3, 26.8, 21.8, 13.4 ppm; IR: vmax 3051, 2934, 2850, 1731, 1619, 1596, 1512, 1498, 1465, 1457, 1441, 1006, 973, 916, 868, 816, 761 cm-1; HRMS (ESI+): m/z calcd for C25H24N3S [M+H]+ 398.1685; found 398.1694.
2-{2-[(E)-2-(4-Methoxyphenyl)ethenyl]-1-phenyl-1H-benzo[d]imidazol-5-yl}benzo[d]thiazole (3{6,10}): a light yellow solid; mp 212–213 °C. 1H NMR (400 MHz, CDCl3): δ 8.47 (s, 1H), 8.15–8.06 (m, 2H), 7.98 (d, J = 15.9 Hz, 1H), 7.92 (d, J = 7.9 Hz, 1H), 7.72–7.58 (m, 3H), 7.55–7.34 (m, 6H), 7.27 (d, J = 6.7 Hz, 1H), 6.89 (d, J = 8.5 Hz, 2H), 6.71 (d, J = 15.9 Hz, 1H), 3.83 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 169.0, 160.8, 154.6, 153.1, 143.7, 138.8, 138.0, 135.6, 135.3, 130.2, 129.4, 129.3, 129.1, 128.9, 127.7, 126.3, 125.0,123.2, 122.7, 121.7, 119.2, 114.5, 111.4, 110.6, 55.5 ppm; IR: vmax 3061, 2937, 2838, 1604, 1529, 1500, 1431, 1020, 907, 889, 835, 792 cm−1; HRMS (ESI+): m/z calcd for C29H22N3OS [M+H]+ 460.1478; found 460.1472.
2-(1-(4-Methoxyphenyl)-2-phenyl-1H-benzo[d]imidazol-5-yl)benzo[d]thiazole (3{7,1}): a light yellow solid; mp 187–188 °C. 1H NMR (400 MHz, CDCl3): δ 8.55 (s, 1H), 8.16 (d, J = 8.5 Hz, 1H), 8.09 (d, J = 8.1 Hz, 1H), 7.92 (d, J = 7.9 Hz, 1H), 7.63 (d, J = 7.2 Hz, 2H), 7.54–7.45 (m, 1H), 7.44–7.24 (m, 7H), 7.05 (d, J = 8.8 Hz, 2H), 3.91 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 169.0, 159.9, 154.5, 154.2, 143.2, 139.8, 135.3, 129.9, 129.8, 129.6, 129.4, 129.1, 128.7, 128.5, 126.3, 125.0, 123.1, 123.0, 121.7, 119.8, 115.3, 111.1, 55.7 ppm; IR: vmax 3060, 2943, 2829, 1712, 1615, 1516, 1469, 1430, 1024, 914, 894, 842, 796 cm−1; HRMS (ESI+): m/z calcd for C27H20N3OS [M+H]+ 434.1322; found 434.1315.
2-(2-(Furan-2-yl)-1-(4-methoxyphenyl)-1H-benzo[d]imidazol-5-yl)benzo[d]thiazole (3{7,6}): a light yellow solid; mp 153–154 °C. 1H NMR (400 MHz, CDCl3): δ 8.49 (s, 1H), 8.09 (d, J = 8.5 Hz, 1H), 8.06 (d, J = 8.1 Hz, 1H),7.90 (d, J = 7.8 Hz, 1H), 7.56–7.52 (m, 1H), 7.48 (dd, J1 = J2 = 7.8 Hz, 1H), 7.40–7.31 (m, 3H), 7.19–7.08 (m, 3H), 6.41–6.35 (m, 1H), 6.18 (d, J = 3.4 Hz, 1H), 3.93 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 168.7, 160.4, 154.3, 145.9, 144.5, 144.1, 143.0, 139.4, 135.1, 129.1, 129.0, 128.3, 126.1, 124.9, 123.1, 123.0, 121.5, 119.5, 115.2, 112.9, 111.6, 110.6, 55.6 ppm; IR: vmax 3057, 2956, 2843, 1598, 1534, 1498, 1475, 1456, 1027, 986, 974, 927, 784 cm−1; HRMS (ESI+): m/z calcd for C25H18N3O2S [M+H]+ 424.1114; found 424.1118.
(E)-2-(1-(4-Methoxyphenyl)-2-styryl-1H-benzo[d]imidazol-5-yl)benzo[d]thiazole (3{7,9}): a light yellow solid; mp 211–212 °C. 1H NMR (400 MHz, CDCl3): δ 8.46 (s, 1H), 8.11 (d, J = 8.5 Hz, 1H), 8.07 (d, J = 8.1 Hz, 1H), 8.00 (d, J = 16.0 Hz, 1H), 7.91 (d, J = 7.8 Hz, 1H), 7.52–7.45 (m, 3H), 7.42–7.31 (m, 6H), 7.24 (d, J = 8.5 Hz, 1H), 7.14 (d, J = 8.5 Hz, 2H), 6.83 (d, J = 16.0 Hz, 1H), 3.95 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 159.1, 153.3, 151.7, 142.3, 137.9, 136.8, 134.8, 134.1, 128.2, 128.0, 127.8, 127.7, 126.6, 126.3, 125.1, 123.8, 121.9, 121.5, 120.5, 118.1, 114.2, 112.5, 109.6, 54.6, 28.6 ppm; IR: vmax 3051, 2957, 2835, 1631, 1514, 1433, 1021, 969, 912, 799 cm−1; HRMS (ESI+): m/z calcd for C29H22N3OS [M+H]+ 460.1478; found 460.1473.
2-(1-Cyclohexyl-2-phenyl-1H-benzo[d]imidazol-5-yl)benzo[d]thiazole (3{8,1}): a light yellow solid; mp 181–182 °C. 1H NMR (400 MHz, CDCl3): δ 8.47 (s, 1H), 8.14 (d, J = 12.2 Hz, 1H), 8.08 (d, J = 12.4 Hz, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.66 (d, J = 8.2 Hz, 2H), 7.59–7.51 (m, 3H), 7.49–7.43 (m, 1H), 7.39–7.31 (m, 1H), 4.44–4.32 (m, 1H), 2.39–2.163 (m, 2H), 2.07–1.84 (m, 4H), 1.81–1.70 (m, 1H), 1.41–1.24 (m, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 168.9, 155.3, 154.3, 143.9,136.1, 135.1, 130.6, 129.9, 129.4, 128.7, 128.0, 126.2, 124.8, 122.9, 121.7, 121.5, 120.0, 113.0, 57.2, 31.5, 25.9, 25.2 ppm; IR: vmax 3052, 2948, 2848, 1622, 1518, 1465, 1443, 1020, 983, 931, 874, 924, 809 cm−1; HRMS (ESI+): m/z calcd for C26H24N3S [M+H]+ 410.1685; found 410.1679.
2-(2-Cyclohexyl-1-propyl-1H-benzo[d]imidazol-5-yl)benzo[d]thiazole (3{9,7}): a light yellow solid; mp 164–165 °C. 1H NMR (400 MHz, CDCl3): δ 8.37 (s, 1H), 8.13 (d, J = 8.5 Hz, 1H), 8.04 (d, J = 8.1 Hz, 1H), 7.87 (d, J = 7.9 Hz, 1H), 7.46 (dd, J1 = J2 = 8.1, 1H), 7.42–7.30 (m, 2H), 4.10 (t, J = 7.3, 2H), 2.89–2.73 (m, 1H), 2.01–1.75 (m, 9H), 1.49–1.35 (m, 3H), 0.99 (t, J =7.5 Hz, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 169.4, 160.8, 154.5, 143.1, 137.1, 135.2, 127.9, 126.2, 124.8, 123.0, 121.6, 121.5, 119.5, 110.0, 45.3, 36.6, 32.2, 26.5, 25.9, 23.6, 11.5 ppm; IR: vmax 3061, 2925, 2846, 1723, 1615, 1502, 1472, 1431, 1015, 982, 918, 869, 819, 799 cm−1; HRMS (ESI+): m/z calcd for C23H26N3S [M+H]+ 376.1842; found 376.1837.

4. Conclusions

In summary, HfCl4 was identified as a highly efficient transition metal Lewis acid catalyst for the synthesis of benzimidazoles from o-phenylenediamines and aldehydes. Our experimental results showed that activated carbon could serve as an excellent solid support for HfCl4 with respect to both catalytic activity and recyclability. The SEM images and EDS spectra of HfCl4/C samples along with the desorption experiments revealed that HfCl4 was tightly adsorpted on activated carbon at ambient temperature and partially desorpted in refluxing ethanol. Based on the fact that HfCl4/C could catalyze the formation of benzimidazoles at ambient temperature, the catalytic effect of HfCl4/C under refluxing conditions should involve both homogeneous and heterogeneous mechanisms. Further application of HfCl4/C in parallel synthesis of 1,2-disubstituted benzimidazoles well exemplified its advantages in terms of catalytic efficiency and facile removal from reaction.

Supplementary Materials

The following are available online at https://www.mdpi.com/2073-4344/10/4/436/s1, Figures S1–S38: The NMR spectra of new compounds.

Author Contributions

Contributions: S.-W.D. and Q.S. conceived and designed the experiments; X.-C.P., S.-S.G., and D.-Y.Z. performed the experiments and analyzed the data; S.-W.D. and Q.S. wrote the paper. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by National Natural Science Foundation of China (21961013) and Innovation Foundation of JXSTNU (YC2019-X27 for X.-C.P.).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Sreerama, R.; Barnali, M.; Balamurali, M.M.; Chanda, K. Synthesis and medicinal applications of benzimidazoles: An overview. Curr. Org. Synth. 2017, 14, 40–60. [Google Scholar]
  2. Carvalho, L.C.R.; Fernandes, E.; Marques, M.M.B. Developments towards regioselective synthesis of 1,2-disubstituted benzimidazoles. Chem. Eur. J. 2011, 17, 12544–12555. [Google Scholar] [CrossRef] [PubMed]
  3. Preston, P.N. Synthesis, reactions, and spectroscopic properties of benzimidazoles. Chem. Rev. 1974, 74, 279–314. [Google Scholar] [CrossRef]
  4. Yadav, G.; Ganguly, S. Structure activity relationship (SAR) study of benzimidazole scaffold for different biological activities: A mini-review. Eur. J. Med. Chem. 2015, 97, 419–443. [Google Scholar] [CrossRef] [PubMed]
  5. Shah, K.; Chhabra, S.; Shrivastava, S.K.; Mishra, P. Benzimidazole: A promising pharmacophore. Med. Chem. Res. 2013, 22, 5077–5104. [Google Scholar] [CrossRef]
  6. Bansal, Y.; Silakari, O. The therapeutic journey of benzimidazoles: A review. Bioorg. Med. Chem. 2012, 20, 6208–6236. [Google Scholar] [CrossRef]
  7. Alamgir, M.; Black, D.S.C.; Kumar, N. Synthesis, reactivity and biological activity of benzimidazoles. Top. Heterocycl. Chem. 2007, 21, 87–118. [Google Scholar]
  8. Wallace, M.B.; Feng, J.; Zhang, Z.; Skene, R.J.; Shi, L.; Caster, C.L.; Kassel, D.B.; Xu, R.; Gwaltney, S.L., II. Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 2362–2367. [Google Scholar] [CrossRef]
  9. Nagawade, R.R.; Shinde, D.B. BF3OEt2 Promoted solvent-free synthesis of benzimidazole derivative. Chin. Chem. Lett. 2006, 17, 453–456. [Google Scholar]
  10. Mayer, J.P.; Lewis, G.S.; McGee, C.; Bankaitis-Davis, D. Solid-phase synthesis of benzimidazoles. Tetrahedron Lett. 1998, 39, 6655–6658. [Google Scholar] [CrossRef]
  11. Kim, S.Y.; Park, K.H.; Chung, Y.K. Manganese (IV) dioxide-catalyzed synthesis of quinoxalines under microwave irradiation. Chem. Commun. 2005, 1321–1323. [Google Scholar] [CrossRef] [PubMed]
  12. Gogoi, P.; Konwar, D. An efficient and one-pot synthesis of imidazolines and benzimidazoles via anaerobic oxidation of carbon–nitrogen bonds in water. Tetrahedron Lett. 2006, 47, 79–82. [Google Scholar] [CrossRef]
  13. Beaulieu, P.L.; Hache, B.; von Moos, E. A practical oxone®-mediated, high-throughput, solution-phase synthesis of benzimidazoles from 1,2-phenylenediamines and aldehydes and its application to preparative scale synthesis. Synthesis 2003, 11, 1683–1692. [Google Scholar] [CrossRef]
  14. Sun, Q.; Wu, R.; Cai, S.; Lin, Y.; Sellers, L.; Sakamoto, K.; He, B.; Peterson, B.R. Synthesis and biological evaluation of analogues of AKT (protein kinase B) inhibitor-IV. J. Med. Chem. 2011, 54, 1126–1139. [Google Scholar] [CrossRef]
  15. Sun, Q.; Wang, C.-J.; Gong, S.-S.; Ai, Y.-J.; Sun, H.-B. Cp2ZrCl2-catalyzed synthesis of 2-aminovinyl benzimidazoles under microwave conditions. Chin. Chem. Lett. 2015, 26, 297–300. [Google Scholar] [CrossRef]
  16. Wu, Y.; Wang, X.; Luo, Y.; Wang, J.; Jian, Y.; Sun, H.; Zhang, G.; Zhang, W.; Gao, Z. Solvent strategy for unleashing the Lewis acidity of titanocene dichloride for rapid Mannich reactions. RSC Adv. 2016, 6, 15298–15303. [Google Scholar] [CrossRef]
  17. Qiu, R.; Xu, X.; Peng, L.; Zhao, Y.; Li, N.; Yin, S. Strong Lewis acids of air-stable metallocene bis(perfluorooctanesulfonate)s as high-efficiency catalysts for carbonyl-group transformation reactions. Chem. Eur. J. 2012, 18, 6172–6182. [Google Scholar] [CrossRef]
  18. Ishihara, K.; Ohara, S.; Yamamoto, H. Direct condensation of carboxylic acids with alcohols catalyzed by hafnium (IV) salts. Science 2000, 290, 1140–1142. [Google Scholar] [CrossRef]
  19. Ishihara, K.; Nakayama, M.; Ohara, S.; Yamamoto, H. Direct ester condensation from a 1:1 mixture of carboxylic acids and alcohols catalyzed by hafnium (IV) or zirconium (IV) salts. Tetrahedron 2002, 58, 8179–8188. [Google Scholar] [CrossRef]
  20. Lundberg, H.; Adolfsson, H. Hafnium-catalyzed direct amide formation at room temperature. ACS Catal. 2015, 5, 3271–3277. [Google Scholar] [CrossRef]
  21. Li, X.-C.; Gong, S.-S.; Zeng, D.-Y.; You, Y.-H.; Sun, Q. Highly efficient synthesis of α-aminophosphonates catalyzed by hafnium(IV) chloride. Tetrahedron Lett. 2016, 57, 1782–1785. [Google Scholar] [CrossRef]
  22. Wang, R.; Chen, J.-Z.; Zheng, X.-A.; Kong, R.; Gong, S.-S.; Sun, Q. Hafnium (IV) triflate as a potent catalyst for selective 1-O-deacetylation of peracetylated saccharides. Carbohydr. Res. 2018, 455, 114–118. [Google Scholar] [CrossRef] [PubMed]
  23. Kong, R.; Han, S.-B.; Wei, J.-Y.; Peng, X.-C.; Xie, Z.-B.; Gong, S.-S.; Sun, Q. Highly efficient synthesis of substituted 3,4-dihydropyrimidin-2-(1H)-ones (DHPMs) catalyzed by Hf(OTf)4: Mechanistic insights into reaction pathways under metal Lewis acid catalysis and solvent-free conditions. Molecules 2019, 24, 364. [Google Scholar] [CrossRef] [PubMed]
  24. Han, S.-B.; Wei, J.-Y.; Peng, X.-C.; Liu, R.; Gong, S.-S.; Sun, Q. Hf(OTf)4 as a highly potent catalyst for the synthesis of Mannich bases under solvent-free conditions. Molecules 2020, 25, 388. [Google Scholar] [CrossRef]
  25. Zhang, Z.-H.; Yin, L.; Wang, Y.-M. An expeditious synthesis of benzimidazole derivatives catalyzed by Lewis acids. Catal. Commun. 2007, 8, 1126–1131. [Google Scholar] [CrossRef]
  26. Nagawade, R.R.; Shinde, D.B. Zirconyl (IV) chloride-promoted synthesis of benzimidazole derivatives. Russ. J. Org. Chem. 2006, 42, 453–454. [Google Scholar] [CrossRef]
  27. Wei, J.-Y.; Han, S.-B.; Peng, X.-C.; Wang, C.-J.; Zeng, D.-Y.; Gong, S.-S.; Sun, Q. Efficient synthesis of fluorinated benzimidazolines, benzoxazolines and benzothiazolines catalyzed by Hf(OTf)4. Heterocycles 2020, 100, 371–382. [Google Scholar]
  28. Trivedi, R.; De, S.K.; Gibbs, R.A. A convenient one-pot synthesis of 2-substituted benzimidazoles. J. Mol. Catal. A Chem. 2006, 245, 8–11. [Google Scholar] [CrossRef]
  29. Sharghi, H.; Aberi, M.; Doroodmanda, M.M. Reusable cobalt(III)-salen complex supported on activated carbon as an efficient heterogeneous catalyst for synthesis of 2-arylbenzimidazole derivatives. Adv. Synth. Catal. 2008, 350, 2380–2390. [Google Scholar] [CrossRef]
  30. Chakrabarty, M.; Karmakar, S.; Mukherjee, R.; Arima, S.; Harigaya, Y. A mild and expedient one-pot synthesis of substituted benzimidazoles in water using a phase-transfer catalyst. Monatsh. Chem. 2009, 140, 375–380. [Google Scholar] [CrossRef]
Catalysts 10 00436 g001
Figure 1. The recyclability of HfCl4/C on the synthesis of 3{1,1}.
Figure 1. The recyclability of HfCl4/C on the synthesis of 3{1,1}.
Catalysts 10 00436 g001
Catalysts 10 00436 g002
Figure 2. Scanning electron microscope (SEM) images and energy dispersive spectrum (EDS) analysis of HfCl4/C (5% w/w) samples. (A) HfCl4/C and (B) HfCl4/C (reflux/cold filtrate for 5 rounds).
Figure 2. Scanning electron microscope (SEM) images and energy dispersive spectrum (EDS) analysis of HfCl4/C (5% w/w) samples. (A) HfCl4/C and (B) HfCl4/C (reflux/cold filtrate for 5 rounds).
Catalysts 10 00436 g002
Catalysts 10 00436 g003
Figure 3. HfCl4/C-Catalyzed parallel synthesis of benzimidazoles (3). a The yield of crude 3 (purity and retention time determined by analytical HPLC). b The isolated yield of 3.
Figure 3. HfCl4/C-Catalyzed parallel synthesis of benzimidazoles (3). a The yield of crude 3 (purity and retention time determined by analytical HPLC). b The isolated yield of 3.
Catalysts 10 00436 g003
Table 1. The effect of catalyst on the synthesis of benzimidazole 3{1,1}.
Table 1. The effect of catalyst on the synthesis of benzimidazole 3{1,1}.
Catalysts 10 00436 i001
EntryCatalystReaction Time (h)Isolated Yield of 3{1,1} (%)
1No12082
2TiCl42067
3ZrOCl2·8H2O2089
4ZrCp2Cl22092
5ZrCl41690
6HfCl41296
Table 2. The effects of temperature and solvent on the synthesis of 3{1,1} with 5 mol% HfCl4.
Table 2. The effects of temperature and solvent on the synthesis of 3{1,1} with 5 mol% HfCl4.
EntryTemperature (°C)SolventReaction Time (h)Isolated Yield of 3{1,1} (%)
120EtOH1696
240EtOH1297
360EtOH497
480EtOH197
580DMF188
680CH3CN1.592
780DCE2490
870THF664
Table 3. The effects of supported HfCl4 catalysts (10 mol%, 5% w/w) on the synthesis of 3{1,1}.
Table 3. The effects of supported HfCl4 catalysts (10 mol%, 5% w/w) on the synthesis of 3{1,1}.
EntrySolid Support Reaction Time 1st/2nd (h)Isolated Yield of 3{1,1} 1st/2nd (%)
1SiO22/492/78
2activated carbon1/196/96
3Al2O31/493/75
4K-10 montmorillonite1/494/79
Table 4. The ethanol desorption experiments of HfCl4/C.
Table 4. The ethanol desorption experiments of HfCl4/C.
MethodWeight Loss (mg)
1st2nd3rd4th5th6th
A a875310
B b000001
a Reflux/hot filtration. b Reflux/cooling/cold filtration.

Share and Cite

MDPI and ACS Style

Peng, X.-C.; Gong, S.-S.; Zeng, D.-Y.; Duo, S.-W.; Sun, Q. Activated Carbon Supported Hafnium(IV) Chloride as an Efficient, Recyclable, and Facile Removable Catalyst for Expeditious Parallel Synthesis of Benzimidazoles. Catalysts 2020, 10, 436. https://doi.org/10.3390/catal10040436

AMA Style

Peng X-C, Gong S-S, Zeng D-Y, Duo S-W, Sun Q. Activated Carbon Supported Hafnium(IV) Chloride as an Efficient, Recyclable, and Facile Removable Catalyst for Expeditious Parallel Synthesis of Benzimidazoles. Catalysts. 2020; 10(4):436. https://doi.org/10.3390/catal10040436

Chicago/Turabian Style

Peng, Xiao-Chong, Shan-Shan Gong, De-Yun Zeng, Shu-Wang Duo, and Qi Sun. 2020. "Activated Carbon Supported Hafnium(IV) Chloride as an Efficient, Recyclable, and Facile Removable Catalyst for Expeditious Parallel Synthesis of Benzimidazoles" Catalysts 10, no. 4: 436. https://doi.org/10.3390/catal10040436

APA Style

Peng, X.-C., Gong, S.-S., Zeng, D.-Y., Duo, S.-W., & Sun, Q. (2020). Activated Carbon Supported Hafnium(IV) Chloride as an Efficient, Recyclable, and Facile Removable Catalyst for Expeditious Parallel Synthesis of Benzimidazoles. Catalysts, 10(4), 436. https://doi.org/10.3390/catal10040436

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop